Abstract
Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of advanced glycation end products (AGEs) in vivo. It is now well established that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being implicated in various types of AGE-related disorders such as diabetic vascular complications, neurodegenerative diseases and cancers. Further, there is accumulating evidence that AGEs and their receptor RAGE interaction elicits oxidative stress generation and subsequently alters gene expression in various types of cells. In addition, digested food-derived AGEs are found to play an important role in the pathogenesis of the AGE-related disorders as well. Indeed, restriction of diet-derived AGEs not only blocks the progression of atherosclerosis and renal injury, but also improves insulin resistance in animal models. AGE-poor diets reduce serum levels of inflammatory biomarkers in patients with diabetes or chronic renal failure. These observations suggest that the restriction of food-derived AGEs or the inhibition of absorption of dietary AGEs may be a novel target for therapeutic intervention in the AGE-related disorders. In this paper, we review the pathological role of food-derived AGEs in various types of disorders and discuss the potential utility of oral adsorbent that inhibits the absorption of AGEs in these devastating diseases.
Keywords: Dietary AGEs, oral adsorbent, atherosclerosis, chronic kidney disease, diabetic vascular complications
Current Pharmaceutical Design
Title: Food-Derived Advanced Glycation end Products (AGEs): A Novel Therapeutic Target for Various Disorders
Volume: 13 Issue: 27
Author(s): Sho-ichi Yamagishi, Seiji Ueda and Seiya Okuda
Affiliation:
Keywords: Dietary AGEs, oral adsorbent, atherosclerosis, chronic kidney disease, diabetic vascular complications
Abstract: Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of advanced glycation end products (AGEs) in vivo. It is now well established that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being implicated in various types of AGE-related disorders such as diabetic vascular complications, neurodegenerative diseases and cancers. Further, there is accumulating evidence that AGEs and their receptor RAGE interaction elicits oxidative stress generation and subsequently alters gene expression in various types of cells. In addition, digested food-derived AGEs are found to play an important role in the pathogenesis of the AGE-related disorders as well. Indeed, restriction of diet-derived AGEs not only blocks the progression of atherosclerosis and renal injury, but also improves insulin resistance in animal models. AGE-poor diets reduce serum levels of inflammatory biomarkers in patients with diabetes or chronic renal failure. These observations suggest that the restriction of food-derived AGEs or the inhibition of absorption of dietary AGEs may be a novel target for therapeutic intervention in the AGE-related disorders. In this paper, we review the pathological role of food-derived AGEs in various types of disorders and discuss the potential utility of oral adsorbent that inhibits the absorption of AGEs in these devastating diseases.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi, Ueda Seiji and Okuda Seiya, Food-Derived Advanced Glycation end Products (AGEs): A Novel Therapeutic Target for Various Disorders, Current Pharmaceutical Design 2007; 13 (27) . https://dx.doi.org/10.2174/138161207781757051
DOI https://dx.doi.org/10.2174/138161207781757051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Psychological Disorders
Current Neuropharmacology Plasmid DNA Manufacturing Technology
Recent Patents on Biotechnology Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Effects of Nannochloropsis Fed on Serum and Tissue Lipids Metabolism in Obese Offspring of Overfed Dams
Current Nutrition & Food Science Adiposity and the Gut - The Role of Gut Hormones
Current Nutrition & Food Science Surrogate Outcomes for Progression in the Initial Stages of Diabetic Retinopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cholesterol, Lipids, Amyloid Beta, and Alzheimers
Current Alzheimer Research Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure
Cardiovascular & Hematological Disorders-Drug Targets Brain Stimulation in Obsessive-Compulsive Disorder (OCD): A Systematic Review
Current Neuropharmacology Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Potential Medicinal Applications of Vanadium and its Coordination Compounds in Current Research Prospects: A Review
Current Bioactive Compounds Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews The Role of 18F-FDG-PET/CT in Infectious Endocarditis and Cardiac Device Infection
Current Molecular Imaging (Discontinued) Bridging the Gap Between Chemistry and Biotechnology - Large Molecules with Potential, How Could Biotechnology Complement Chemistry?
Current Organic Chemistry Cytokines as Therapeutic Targets to Reduce Cardiovascular Risk in Chronic Inflammation
Current Pharmaceutical Design Different Pharmacokinetic Responses to an Acute Dose of Inorganic Nitrate in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Immune System Modulators with Antidepressant Effects: Evidence from Animal Models
CNS & Neurological Disorders - Drug Targets Vascular Smooth Muscle Relaxation by a Lectin from Pisum arvense: Evidences of Endothelial NOS Pathway
Protein & Peptide Letters Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Modulation of a Cellular Transport Activity by Capsicum Extracts
Current Bioactive Compounds